Synapse - Hematologic Malignancies, Division of

Results (13375)

A global, phase 3, randomized, double-blind study to evaluate safety and efficacy of selinexor, an XPO-1 inhibitor, in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis (XPORT-MF-034)

Meeting Abstract

Maher, K.; Rampal, R. K.; Bose, P.; Podoltsev, N. A.; Harrison, C. N.; Hong, J.; Wang, X.; Chamoun, K.; Mascarenhas, J.
Blood (2023)

Fulltext@MSK | Save

Fixed-duration pirtobrutinib combined with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Updated results, including MRD data, from the BRUIN phase 1b study

Meeting Abstract

Roeker, L. E.; Woyach, J. A.; Cheah, C. Y.; Coombs, C. C.; Shah, N. N.; Wierda, W. G.; Patel, M.; Tsai, D. E.; Nair, B.; Wang, C.; more...
Blood (2023)

Fulltext@MSK | Save

Preconditioning single high-dose palifermin alters the posttransplant inflammatory cytokine profile

Meeting Abstract

Schulz, E.; Holtzman, N. G.; Ostojic, A.; Pirsl, F.; Steinberg, S. M.; Curtis, L. M.; Shaffer, B. C.; Heller, T.; Carpenter, A.; Hakim, F. T.; more...
Blood (2023)

Fulltext@MSK | Save

SARS-CoV-2 infection does not lead to progression of monoclonal gammopathy of undetermined significance: Results from the population-based iStopMM screening study

Meeting Abstract

Palmason, R.; Ekberg, S.; Eythorsson, E.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Crowther, M.; Reed, E. R.; Oskarsson, J.; Sigurdardottir, G. A.; Aspelund, T.; more...
Blood (2023)

Fulltext@MSK | Save

Engraftment syndrome during autologous stem cell transplant in Hodgkin lymphoma patients treated with checkpoint inhibitors: A multi-center retrospective analysis

Meeting Abstract

Taranto, E.; Hwang, W. T.; Alfaro, M.; Surapaneni, A. S.; Gill, S. K.; Feldman, T.; Randall, M. P.; Spinner, M. A.; Furqan, F.; Shah, N. N.; more...
Blood (2023)

Fulltext@MSK | Save

Efficacy of brentuximab vedotin maintenance therapy following autologous stem cell transplantation in patients with relapsed/refractory classical Hodgkin lymphoma with and without pre-transplant exposure to novel agents

Meeting Abstract

Falade, A. S.; Redd, R. A.; Shah, H.; Baron, K.; Iyengar, S.; Desai, S. H.; Ansell, S. M.; Micallef, I.; Nedved, A.; Ganesan, N.; more...
Blood (2023)

Fulltext@MSK | Save

Clinical Factors but not somatic mutations predict for survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplant: Analysis of the North American myelofibrosis transplant outcome (NAMTO) study

Meeting Abstract

Ajufo, H.; Derkach, A.; Rampal, R. K.; Famulare, C.; Nemirovsky, D.; Chervin, J.; Ho, V.; Gupta, V.; Viswabandya, A.; Deeg, H. J.; more...
Blood (2023)

Fulltext@MSK | Save

Manufacturing, characterization and anti-tumor activity of allogeneic CD19-CAR cytokine-induced killer (CIK) cells engineered with non-viral sleeping beauty transposon system and armored with IL-18

Meeting Abstract

Contreras-Ruiz, L.; Pace, B.; Kohnke, D. E.; Viruet, L.; Adams, M.; Krisko, J. F.; Leesnitzer, N.; Velie, M.; Tettamanti, S.; Pisani, I.; more...
Blood (2023)

Fulltext@MSK | Save

Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals - An updated analysis using premier healthcare database

Meeting Abstract

Tan, C. R.; Kim, N.; Chinaeke, E.; Hester, L.; Fowler, J.; Gifkins, D.; Lin, D.; Walker, S.; Fu, A. Z.; Wu, B.
Blood (2023)

Fulltext@MSK | Save

Efficacy and safety of elranatamab in Black patients with relapsed/refractory multiple myeloma (RRMM): A Subgroup analysis of the magnetismm studies

Meeting Abstract

Varshavsky-Yanovsky, A.; Jethava, Y.; Stevens, D. A.; Nooka, A. K.; Stiff, P. J.; Perez-Cruz, I.; Leip, E.; Lesokhin, A.
Blood (2023)

Fulltext@MSK | Save